TGFBR1 and neoplasm: Galunisertib (LY2157299), a small-molecule selective inhibitor of the TGFBR1/ALK5 (41, 42), has been developed by Eli Lilly as an anticancer therapeutic to target the direct and indirect effect of TGF-β on tumor growth.